Enveric Biosciences, Inc. — Director's Dealing 2021

Sep 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Enveric Biosciences, Inc. (ENVB)
CIK: 0000890821
Period of Report: 2021-09-16

Reporting Person: Thompson Bradley George (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-16	Stock Options	$0.94	A	53160	Acquired	2026-04-05	Common Stock (53160)	Direct

Footnotes

F1: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F3: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F4: Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.